The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has ...

SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company ...

Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...

Four-year results of a phase III trial showed that budesonide oral suspension (Eohilia) for eosinophilic esophagitis was well ...

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

The FDA has accepted a priority review of a new biannual HIV prevention injection, with a decision expected by June 19, 2025.

The leading Extensive-Stage Small Cell Lung Cancer Companies such as Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, ...

Regenerative Medicine Advanced Therapy (RMAT) designation follows Phase Ib 36-month data Study demonstrated favorable safety profile and continued positive trends in assessed clinical outcome measures ...

Extends US patent protection until 2042MONTREAL and CHARLOTTE, N.C., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the ...

Zongertinib would be the first orally administered, targeted therapy for previously treated patients with (NSCLC), if approved The application for this investigational treatment is based on positive ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the company’s twice-yearly ...